Neslihan Ozyurt

Dr. Neslihan Ozyurt

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EKEbru Karci
Ebru Karci
ABAhmet Bilici
Ahmet Bilici
BKBuket Bayram Kuvvet
Buket Bayram Kuvvet
MCMelisa Celayir
Melisa Celayir
NONeslihan Ozyurt
Neslihan Ozyurt
OYOzcan Yildiz
Ozcan Yildiz
Background/Objectives: Following the results of the phase 3 KEYNOTE-522 trial, the U.S. Food and Drug Administration approved pembrolizumab, a humanized IgG4 kappa monoclonal antibody, in combination with neoadjuvant chemotherapy as a new standard of care for high-risk early-stage triple-negative breast cancer (TNBC). This retrospective, multicenter study in Türkiye assessed the real-world efficacy and safety of neoadjuvant pembrolizumab combined with chemotherapy in early-stage TNBC. Methods: The study included 108 patients treated between 2021 and 2023 across 14 oncology centers. Three distinct neoadjuvant regimens incorporating pembrolizumab were administered at the discretion of the treating physicians. The primary outcomes were the pathological complete response (pCR) rate after neoadjuvant therapy and the 2-year event-free survival (EFS) and overall survival (OS) rates. Results: The observed pCR rate was 63.9%, closely mirroring the 64.8% reported in the KEYNOTE-522 trial. At the two-year mark, the EFS rate was 87.2% and the OS rate was 92.3%. Multivariable analysis identified pCR as the sole independent predictor of both EFS and OS. The safety profile was consistent with previous clinical trial data, with most adverse events being of grade 1–2 in severity. Conclusions: These findings provide valuable real-world confirmation of the efficacy and safety of neoadjuvant pembrolizumab–chemotherapy in early-stage TNBC, complementing evidence from randomized trials.

14 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
NONeslihan Ozyurt
Neslihan Ozyurt
ATAykut Turhan
Aykut Turhan
Background: Bladder cancer has diverse clinical outcomes, even in patients receiving curative treatment. Traditional clinicopathological indicators inadequately assess individual risk. The Gustave Roussy Immune Score (GRIm-score), which combines albumin, lactate dehydrogenase (LDH), and neutrophil-to-lymphocyte ratio (NLR), is a prognostic factor for solid tumors; however, its role in bladder cancer remains unclear. Methods: In this retrospective cohort study, patients with bladder cancer confirmed through histopathology received bladder-preserving multimodal therapy or radical cystectomy between October 2010 and April 2025. Participants were grouped into low (0–1) and high (2–3) GRImS categories for analysis. The study examined cancer-specific survival (CSS) and the secondary outcomes of progression-free survival (PFS), overall survival (OS), and treatment completion. Survival analyses were performed using the Kaplan–Meier method and Cox proportional hazard regression. Results: A total of 89 patients participated in the study, with 73 (82.0%) and 16 (18.0%) having low and high GRIm-Score. During a median follow-up of 21.5 months, patients with a high GRIm-score had significantly shorter PFS, OS, and CSS than those with a low GRIm-score. The median CSS was 14.07 months for the high GRIm-score group and 27.75 months for the low GRIm-score group (p = 0.004). In multivariable Cox regression analysis, a high GRIm-score was independently associated with an increased cancer-specific mortality risk (hazard ratio [HR] 2.48, 95% confidence interval [CI], 1.31–4.67; p = 0.005). Treatment completion was lower in the high GRIm-score group (31.3% vs. 64.4%, p = 0.031). Conclusions: The GRIm-score serves as an independent prognostic indicator for cancer-specific survival in patients with bladder cancer undergoing curative treatment and is related to therapy completion.

10 December 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
ATAykut Turhan
Aykut Turhan
NONeslihan Ozyurt
Neslihan Ozyurt
MSMüge Sönmez
Müge Sönmez
Magnesium is essential for cellular metabolism, and its deficiency has been associated with adverse outcomes in various cancers. The MDS, which considers factors such as diuretic and proton pump inhibitor use, alcohol consumption, and kidney function, is a practical indicator of Mg deficiency. This retrospective cohort study assessed 200 patients with EC treated between 2010 and 2024 to explore the prognostic value of MDS. Patients were divided into low (0–1), intermediate (2), and high (≥3) MDS risk categories. Higher MDSs were significantly associated with older age, comorbid conditions, hypertension, diabetes, and reduced serum magnesium and vitamin D levels (all p < 0.001). Kaplan–Meier analysis revealed that patients with high MDSs experienced notably shorter overall and progression-free survival than those with lower scores. Multivariate Cox regression analysis identified age, tumor grade, lymphovascular invasion, and stage as independent prognostic factors, excluding those for MDS. These results indicate that although MDS is associated with comorbidities, biochemical deficiencies, and poorer unadjusted survival, it does not independently predict the prognosis of EC. The MDS could be a straightforward and cost-effective tool for identifying metabolically vulnerable patients, especially among the elderly, and merits further validation in prospective studies.

30 July 2025 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ATAykut Turhan
Aykut Turhan
NONeslihan Ozyurt
Neslihan Ozyurt
Aims: To evaluate the relationship between age at diagnosis and molecular subtypes of breast cancer in a retrospective single-center cohort at the Ordu University Training and Research Hospital. Methods: We reviewed the data of 139 female patients diagnosed with invasive breast carcinoma between January 2020 and March 2025. Clinical and pathological data, including age at diagnosis, body-mass index (BMI), TNM stage, histological subtype and grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, and Ki-67 index, were extracted from the medical records. Tumors were classified into luminal A, luminal B, HER2-enriched, and triple-negative subtypes. Patients were stratified into three age groups:

8 October 2025 in Research Square
Verified
Preprint
Open access
PDF file
NONeslihan Ozyurt
Neslihan Ozyurt
MSMüge Sönmez
Müge Sönmez
Background: Second primary malignancies (SPMs) have become an increasingly recognized clinical entity in modern oncology as advances in treatment prolong survival. This study aimed to investigate the incidence of SPMs in patients with solid tumors, to evaluate associated demographic and clinical factors, and to examine the potential prognostic role of the Magnesium Depletion Score (MDS). Methods: This retrospective cohort study included 1,027 patients diagnosed with solid tumors between 2010 and 2023, with complete follow-up data available. Patients were stratified according to the presence of SPM. Demographic, clinical, and lifestyle variables were compared. Survival analyses were performed using the Kaplan–Meier method, and risk factors associated with SPM were assessed using univariable logistic regression. Results: SPMs were identified in 7.1% of patients. Patients with SPMs were more frequently diagnosed at earlier stages (28.8% stage I) and had significantly longer overall survival compared to those without SPMs (median OS: 7.89 vs. 2.52 years; p < 0.05). Logistic regression analysis revealed that former smoking (OR = 1.99), presence of diabetes (OR = 1.78), and each one-unit increase in MDS (OR = 1.59) were significantly associated with SPM development. Advanced stage at initial diagnosis was inversely associated with the likelihood of SPM occurrence. Conclusion: SPMs are more commonly observed in patients diagnosed at an earlier stage and with longer survival. MDS may serve as a potential biomarker for predicting SPM risk. These findings highlight the importance of long-term follow-up and metabolic assessment in cancer survivors.

1 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
NONeslihan Ozyurt
Neslihan Ozyurt
AAAli Alkan
Ali Alkan
BGBurcu Gülbağcı
Burcu Gülbağcı
MSMustafa Seyyar
Mustafa Seyyar
EAESRA AŞIK
ESRA AŞIK
MDMutlu Doğan
Mutlu Doğan
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis. Effective prognostic tools are essential to guide risk-adapted strategies following neoadjuvant chemotherapy (NACT). In this multicenter retrospective study, we evaluated 690 patients with locally advanced TNBC treated between 2010 and 2023 across 25 oncology centers. Patients were stratified into CPS-EG risk groups: low (0–1), intermediate (2–3), and high (≥4). The CPS-EG score was strongly associated with pathological complete response (pCR), recurrence, disease-free survival (DFS), and overall survival (OS). Five-year DFS rates were 80.6%, 53.2%, and 31.5% in the low-, intermediate-, and high-risk groups, respectively, while OS rates were 76.7%, 53.2%, and 48.8% (p<0.001). Multivariate analysis confirmed CPS-EG as an independent predictor of both DFS and OS after adjusting for clinicopathological factors. These findings highlight the CPS-EG score as a simple, cost-effective, and widely applicable prognostic tool that may improve post-NACT risk stratification and support treatment decisions, especially in resource-limited oncology settings.